ArticlePLoS computational biology2021
The value of decreasing the duration of the infectious period of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
Article in PLoS computational biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Cost of the COVID-19 pandemic versus the cost-effectiveness of mitigation strategies in EU/UK/OECD: a systematic review.BMJ open · 2023Pooled it
- What Is the Economic Benefit of Annual COVID-19 Vaccination From the Adult Individual Perspective?The Journal of infectious diseases · 2024Article
- Modeling Nursing Home Harms From COVID-19 Staff Furlough Policies.JAMA network open · 2024Article
- Cost-effectiveness of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) testing and isolation strategies in nursing homes.Infection control and hospital epidemiology · 2024Article
- How the Timing of Annual COVID-19 Vaccination of Nursing Home Residents and Staff Affects Its Value.Journal of the American Medical Directors Association · 2024Article
- The potential epidemiologic, clinical, and economic value of a universal coronavirus vaccine: a modelling study.EClinicalMedicine · 2024Article
- Infectious Disease Modeling with Socio-Viral Behavioral Aspects-Lessons Learned from the Spread of SARS-CoV-2 in a University.Tropical medicine and infectious disease · 2022Article
- Optimizing global COVID-19 vaccine allocation: An agent-based computational model of 148 countries.PLoS computational biology · 2022Article
- Maintaining face mask use before and after achieving different COVID-19 vaccination coverage levels: a modelling study.The Lancet. Public health · 2022Article
- Economic Burden of COVID-19: A Systematic Review.ClinicoEconomics and outcomes research : CEOR · 2022Review
- Lower probability and shorter duration of infections after COVID-19 vaccine correlate with anti-SARS-CoV-2 circulating IgGs.PloS one · 2022Article
- COVID-19 Eradication for Vaccine Equity in Low Income Countries.Indian pediatrics · 2021Article
- Synergistic interventions to control COVID-19: Mass testing and isolation mitigates reliance on distancing.PLoS computational biology · 2021Article
- Lives and Costs Saved by Expanding and Expediting Coronavirus Disease 2019 Vaccination.The Journal of infectious diseases · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Finding medications or vaccines that may decrease the infectious period of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could potentially reduce transmission in the broader population. We developed a computational model of the U.S. simulating the spread of SARS-CoV-2 and the potential clinical and economic impact of reducing the infectious period duration. Simulation experiments found that reducing the average infectious period duration could avert a median of 442,852 [treating 25% of symptomatic cases, reducing by 0.5 days, reproductive number (R0) 3.5, and starting treatment when 15% of the population has been exposed] to 44.4 million SARS-CoV-2 cases (treating 75% of all infected cases, reducing by 3.5 days, R0 2.0). With R0 2.5, reducing the average infectious period duration by 0.5 days for 25% of symptomatic cases averted 1.4 million cases and 99,398 hospitalizations; increasing to 75% of symptomatic cases averted 2.8 million cases. At $500/person, treating 25% of symptomatic cases saved $209.5 billion (societal perspective). Further reducing the average infectious period duration by 3.5 days averted 7.4 million cases (treating 25% of symptomatic cases). Expanding treatment to 75% of all infected cases, including asymptomatic infections (R0 2.5), averted 35.9 million cases and 4 million hospitalizations, saving $48.8 billion (societal perspective and starting treatment after 5% of the population has been exposed). Our study quantifies the potential effects of reducing the SARS-CoV-2 infectious period duration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.